GDF15 and ACE2 stratify COVID-19 patients according to severity while ACE2 mutations increase infection susceptibility.

Autor: Torrens-Mas, Margalida, Perelló-Reus, Catalina M., Trias-Ferrer, Neus, Ibargüen-González, Lesly, Crespí, Catalina, Maria Galmes-Panades, Aina, Navas-Enamorado, Cayetano, Sanchez-Polo, Andres, Piérola-Lopetegui, Javier, Masmiquel, Luis, Socias Crespi, Lorenzo, Barcelo, Carles, Gonzalez-Freire, Marta
Předmět:
Zdroj: Frontiers in Cellular & Infection Microbiology; 7/22/2022, Vol. 12, p1-21, 21p
Abstrakt: Coronavirus disease 19 (COVID-19) is a persistent global pandemic with a very heterogeneous disease presentation ranging from a mild disease to dismal prognosis. Early detection of sensitivity and severity of COVID-19 is essential for the development of new treatments. In the present study, we measured the levels of circulating growth differentiation factor 15 (GDF15) and angiotensinconverting enzyme 2 (ACE2) in plasma of severity-stratified COVID-19 patients and uninfected control patients and characterized the in vitro effects and cohort frequency of ACE2 SNPs. Our results show that while circulating GDF15 and ACE2 stratify COVID-19 patients according to disease severity, ACE2 missense SNPs constitute a risk factor linked to infection susceptibility. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index